326 related articles for article (PubMed ID: 29625604)
1. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
2. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
3. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
Liao Z; Li F; Zhang C; Zhu L; Shi Y; Zhao G; Bai X; Hassan S; Liu X; Li T; Xing P; Zhao J; Zhang J; Xing R; Teng S; Yang Y; Chen K; Yang J
Exp Mol Med; 2019 Feb; 51(3):1-11. PubMed ID: 30816108
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
7. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Yang C; Feng W; Wu D
J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
[TBL] [Abstract][Full Text] [Related]
9. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
[TBL] [Abstract][Full Text] [Related]
12. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
13. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
14. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
[TBL] [Abstract][Full Text] [Related]
15. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
16. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
17. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
[Next] [New Search]